Suppr超能文献

马来西亚肾移植的成本与效用

The Cost and Utility of Renal Transplantation in Malaysia.

作者信息

Bavanandan Sunita, Yap Yok-Chin, Ahmad Ghazali, Wong Hin-Seng, Azmi Soraya, Goh Adrian

机构信息

Department of Nephrology, Hospital Kuala Lumpur, Malaysia.

Department of Pediatrics, Hospital Kuala Lumpur Malaysia.

出版信息

Transplant Direct. 2015 Nov 20;1(10):e45. doi: 10.1097/TXD.0000000000000553. eCollection 2015 Nov.

Abstract

UNLABELLED

Kidney transplantation is the optimal therapy for the majority of patients with end-stage renal disease. However, the cost and health outcomes of transplantation have not been assessed in a middle-income nation with a low volume of transplantation, such as Malaysia.

AIM AND METHODS

This study used microcosting methods to determine the cost and health outcomes of living and deceased donor kidney transplantation in adult and pediatric recipients. The perspective used was from the Ministry of Health Malaysia. Cost-effectiveness measures were cost per life year (LY) and cost per quality-adjusted LYs. The time horizon was the lifetime of the transplant recipient from transplant to death.

RESULTS

Records of 206 KT recipients (118 adults and 88 children) were obtained for microcosting. In adults, discounted cost per LY was US $8609(Malaysian Ringgit [RM]29 482) and US $13 209(RM45 234) for living-donor kidney transplant (LKT) and deceased donor kidney transplant (DKT), respectively, whereas in children, it was US $10 485(RM35 905) and US $14 985(RM51 317), respectively. Cost per quality-adjusted LY in adults was US $8826 (RM30 224) for LKT and US $13 592(RM46 546) for DKT. Total lifetime discounted costs of adult transplants were US $119 702 (RM409 921) for LKT, US $147 152 (RM503 922) for DKT. Total costs for pediatric transplants were US $154 841(RM530 252) and US $159 313(RM545 566) for the 2 categories respectively.

CONCLUSIONS

Both LKT and DKT are economically favorable for Malaysian adult and pediatric patients with ESRD and result in improvement in quality of life.

摘要

未标注

肾移植是大多数终末期肾病患者的最佳治疗方法。然而,在马来西亚这样一个移植量低的中等收入国家,移植的成本和健康结果尚未得到评估。

目的和方法

本研究采用微观成本核算方法,以确定成人和儿童受者活体和尸体供肾移植的成本和健康结果。所采用的视角是马来西亚卫生部的视角。成本效益指标为每生命年成本(LY)和每质量调整生命年成本。时间范围是从移植到死亡的移植受者的一生。

结果

获取了206名肾移植受者(118名成人和88名儿童)的记录用于微观成本核算。在成人中,活体供肾移植(LKT)和尸体供肾移植(DKT)每生命年的贴现成本分别为8609美元(29482马来西亚林吉特[RM])和13209美元(45234马来西亚林吉特),而在儿童中,分别为10485美元(35905马来西亚林吉特)和14985美元(51317马来西亚林吉特)。成人LKT每质量调整生命年成本为8826美元(30224马来西亚林吉特),DKT为13592美元(46546马来西亚林吉特)。成人移植的终身贴现总成本,LKT为119702美元(409921马来西亚林吉特),DKT为147152美元(503922马来西亚林吉特)。两类儿童移植的总成本分别为154841美元(530252马来西亚林吉特)和159313美元(545566马来西亚林吉特)。

结论

对于马来西亚患有终末期肾病的成人和儿童患者,活体和尸体供肾移植在经济上都是有利的,并且能改善生活质量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b449/4946449/70084411498d/txd-1-e45-g010.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验